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Abstract 
The development of bioactive surgical additives, 
which are being used to regulate the inflammation 
and increase the speed of healing process, is one of 
the great challenges in oral surgery. Platelet-rich fibrin 
(PRF) is a second-generation platelet concentrate who 
was defined as an autologous leukocyte and PRF bio-
material, in which, platelets and leukocytes are collect-
ed with high efficiency such that the growth factors 
will able to release gradually during at least 1 week. 
The biologic effect of this fibrin matrix is: angiogenesis, 
immune control, harnessing the circulating stem cells, 
and wound protection by epithelial cover. The follow-
ing article attempts to summarize our clinical cases 
regarding the technique of using PRF, focusing on its 
preparation, advantages of using it in oral surgery. 
Three cases with different clinical diagnoses were tak-
en for this study in order to show the possible ways 
of application of PRF in the surgical field. In the first 
case, it is a 53 year-old female patient who has been 
diagnosed with osteonecrosis of the alveolar ridge 
during the examination in the projection of the first 
lower right molar. In the second case, PRF application 
was administered to a 41 year-old female patient di-
agnosed with radicular cyst on the upper left second 
incisor. The third case involved a 47 year-old male pa-
tient with diagnosed gangrenous roots in the upper 
right first and second premolars ant the second molar 
in which the PRF application was intended to achieve 
alveolar bridge augmentation. PRF was prepared with 
blood drawn from individuals using technique du to 
PRF protocol. Both types of PRF (I and A-PRF) were 
 applied independently in the first case, and in the sec-
ond and third cases a bone graft was placed together 
with PRF.
The soft and bone tissue management in all our cases 
show process of neovascularization through the PRF 
clot and the epithelial covering development. In spite 
of the infectious and inflammatory statement of such 
sockets, rapid healing of the wound was observed 
without pain, dryness, or purulent complications. The 
results of the observed cases showed that biologic 
effect of PRF was revealed trough achieved angiogen-
esis, immune control, harnessing the circulating stem 
cells, and wound protection by epithelial cover. 
PRF alone or in combination with other biomaterials 
seems to have several advantages and indications in 
oral surgery, due it is a minimally invasive technique 
with low risks and satisfactory results.
Key words:  Platelet-rich fibrin, Blood platelet, Bone 
 regeneration, Soft tissue regeneration. 
1. Introduction
Various biomaterials have been used for bone and tis-
sue regeneration in addition to autogenous and allo-
genic grafts but not a single graft material is consid-
ered as gold standard for the treatment of intrabony 
and soft tissue defects. 
Platelet-rich fibrin (PRF) which belongs to a second 
generation of platelet concentrates [1, 2], was first 
Journal of Hygienic Engineering and Design
146
 developed in France, by Dr. Choukroun et al., in 2000 
[3], for specific use in oral and maxillofacial surgery. 
PRF is a new generation of platelet concentrate tech-
niques that allow one to obtain fibrin membranes en-
riched with platelets and grow factors, starting from an 
anticoagulant-free blood harvest [4]. 
PRF has a dense fibrin network with: leukocytes, cy-
tokines, structural glycoproteins [5], and also growth 
factors such as transforming growth factor β1, plate-
let-derived growth factor, vascular endothelial growth 
factor and glycoproteins such as thrombospondin-1 
[6]. Leukocytes that are concentrated in PRF scaffold 
play an important role in growth factor release, im-
mune regulation [7], anti-infectious activities [8], and 
matrix remodeling during wound healing. 
The PRF clot forms a strong natural fibrin matrix, which 
concentrates almost all the platelets and growth fac-
tors of the blood harvest [7, 9] and shows a complex ar-
chitecture as a healing matrix with unique mechanical 
properties which makes it distinct from other platelet 
concentrates. 
PRF has immune functions like chemotaxis as leuko-
cytes present in PRF degranulates during activation and 
releases cytokines like IL-1, IL-4, IL-6 and TNF-α. PRF also 
contains anti-inflammatory cytokine such as IL-4 which 
requires further research [7]. PRF has been described as 
“an immune and platelet concentrate in a single fibrin 
membrane, containing all constituents of the blood 
sample favorable for healing and immunity” [10]. 
The leukocytes present within PRF play a role as an 
anti-infective action, immunological regulation, abili-
ty to produce a great number of vascular endothelial 
growth factors (VEGF), which has caught the interest 
and curiosity of researchers [11, 12]. 
Another added advantage of PRF is the presence 
of natural fibrin network in PRF which protects the 
growth factors from proteolysis [13, 14]. PRF also favors 
the development of micro vascularization leading to a 
more efficient cell migration. 
PRF dissolves slowly after use, keeping it stable for a 
longer period of time, preserving the fibrin mesh, al-
lowing longer cytokine life and a higher concentration 
of platelets, leukocytes, circulating stem cells incor-
porated within the physiological matrix of fibrin. Con-
sequently, growth factors are allowed to be released 
more slowly at the surgical site, persisting for a longer 
time during wound cicatrisation, from 7 to 28 days [15, 
16]. 
The following article attempts to summarize the rele-
vant literature regarding the technique of using plate-
let rich fibrin (PRF), focusing on its preparation, and 
advantages of using it in clinical applications in oral 
surgery.
2. Materials and Methods
The study was conducted in accordance with the Hel-
sinki Declaration. Written informed consent was ob-
tained from the patient after a thorough explanation 
of the nature, risks, and benefits of the clinical appli-
cation. 
2.1 Materials (patients)
Three cases with different clinical diagnoses were tak-
en for this study in order to show the possible ways 
of application of PRF in the surgical field. In the first 
case, it is a 53 year-old female patient who has been 
diagnosed with osteonecrosis of the alveolar ridge 
during the examination in the projection of the first 
lower right molar. In the second case, PRF application 
was administered to a 41 year-old female patient di-
agnosed with radicular cyst on the upper left second 
incisor. The third case involved a 47 year-old male pa-
tient with diagnosed gangrenous roots in the upper 
right first and second premolars ant the second molar 
in which the PRF application was intended to achieve 
alveolar bridge augmentation. 
2.2 Methods
2.1.1 PRF protocol
The PRF protocol is very simple. A blood sample was 
taken without anticoagulant in 10 mL tubes, which 
were immediately centrifuged at different rotation per 
minute according to what kind of PRF was made (Fig-
ure 1). A-PRF tubes (red tubes) used to get clots and 
make membranes and I-PRF tubes (orange tubes) used 
to get liquid PRF for injection. The tubes were under 
vacuum and the blood stops being collected when the 
tubes were full. The blood drawing has to be as fast as 
possible. It’s essential for the PRF clot quality. 
Figure 1. PRF centrifuge by Dr. J. Choukroun with A-PRF 
tubes (red tubes) and I-PRF tubes (orange tubes)
PRF production protocol attempts to accumulate 
platelets and the released cytokines in a fibrin clot [17]. 
They mostly accumulate in the lower part of the fibrin 
clot at the junction between the red corpuscles (red 
thrombus) and the PRF clot itself. It turns out that the 
PRF red extremity would be even more effective than 
the higher part of the fibrin clot. 
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The duration of time between blood collection and 
centrifugation process was an important parameter 
affecting the success and clinical outcome of this pro-
cedure. The absence of anticoagulant implied the acti-
vation in a few minutes of most platelets of the blood 
sample in contact with the tube walls and the released 
of the coagulation cascades. Slow handling of blood 
to centrifugation process is resulting in diffuse polym-
erization of fibrin leading to the formation of a small 
blood clot with irregular consistency. 
Working temperature must be between 21 and 30 0C, 
because the clot cannot be produced if the tempera-
ture is lower. 
Number of collected tubes was minimum at least 2, and 
maximum 12, always set balanced 2 by 2 because in 
contrary, there will be vibrations during the centrifuga-
tion. We used the color code to balance the tubes easily. 
2.1.2 Protocol for A-PRF
The centrifuge must be set at 13 x 100 rpm/8 minutes. 
At the end of centrifugation, the lid was opened au-
tomatically. After that we removed the tube and the 
caps, and placed the tubes in the sterile tube holder 
and let it them to “rest” around 5 minutes. 
- PRF clots removal:
First, we took the fibrin clot into the opened tube with 
the sterile PRF forceps and separated the fibrin clot 
from the red cells. We placed the clot on the mini-tray 
covered with a gauze and use the closed scissors to 
peel off the red clot (Figure 3). The PRF clots were putt-
ed on the BoX grid, covered with the tray and then we 
putted the lid on.
The PRF BoX was used to:
• Get membranes of constant thickness and kept 
them always hydrated and to remain them intact for 
2 or 3 hours (not to be dehydrated). 
Figure 2. Layers of centrifuged blood samples, 
tube with three fractions: a) supernatant-acellular  
plasma at the top, b) fibrin clot in the middle of the tube, 
c) red corpuscles at the bottom
• Recover the exudate and
• Produce ‘‘plugs’’ of PRF for socket extraction filling 
(which was done in the white cylinders, with the 
piston). 
We kept the exudate recovered at the bottom of the 
box in order to:
• Hydrate biomaterials,
• Flush the surgical sites, sockets and cysts and
• Preserve the autogenous bone blocks (rather than 
in saline). 
2.1.3 Protocol for I-PRF
The centrifuge must be set at 7 x 100 rpm/3 minutes. 
At the end of the spin, supernatant was formed on the 
surface of the orange tube. In order to collect the liq-
uid, we penetrated the cap with a 21G needle (green) 
mounted on a syringe. Needle was placed in the mid-
dle of the I-PRF supernatant, against the wall of the 
tube for better visibility. Aspiration was done until the 
level of the red blood cells raises up to the needle bev-
el. I-PRF remained liquid for about 10 -12 minutes, then 
clotted. The injection was done before the end of these 
10 - 12 minutes (Figure 4). 
Figure 3. a) Removing red part from PRF clot, 
b) PRF membrane
Figure 4. Aspiration of I-PRF
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We used the I-PRF for injection: a). into the soft tis-
sues b). in the bone graft where we mix the granules 
with the A-PRF, and poured the I-PRF drop by drop for 
avoiding an overflow. After that we waited a few sec-
onds and continued until we obtained the complete 
coagulation of the biomaterials (in less than a minute) 
c). into the sinus, after the filling. The granules were 
fixed and coagulated, and d). I-PRF was used to coagu-
late the biomaterials before application. 
3. Results and Discussion
3.1 Results - clinical cases
In surgical procedures, PRF could serve as a resorbable 
membrane for guided bone regeneration (GBR), pre-
venting the migration of non-desirable cells into bone 
defect and providing a space that allows the immigra-
tion of osteogenic and angiogenic cells and permits 
the underlying blood clot to mineralize. 
Figure 5 shows the case of wound with osteonecrosis 
after tooth extraction done in patient with diabetes 
mellitus. The epithelization of the wound was not suc-
cessfully attained even after 3 mounts of the extraction 
and necrotic bone was formed. A surgical procedure 
was performed with abolishing of the necrotic bone till 
getting to the healthy tissue and making bloody area 
on which PRF membrane was applied. Quickly, a neo-
vascularization formed through the PRF membrane 
and the epithelial covering developed. Finally, in spite 
of the infectious and inflammatory statement of such 
defect, rapid healing of the wound was observed with-
out pain, dryness, or purulent complications. 
A current clinical example deals with the filling of bone 
defect with PRF caused by radicular cyst (Figure 6). Af-
ter removal of inflammation tissue, the bone defect 
was grafted with sticky bone, mass of grafting material 
combined of Bio-OSS and PRF exudate. The PRF exu-
date was collected in the bottom of PRF box during 
straining of PRF membranes. It is very rich in proteins 
(fibronectin and vitronectin). PRF exudate was than ap-
plied drop by drop on the bone substituent and left to 
indurate together. That kind of mass was insert in bone 
cavity and covered with PRF membrane. All that was 
covered with mucoperiosteal flap and sutured. Control 
examine reveal fine healing wound, without any symp-
toms of inflammation. 
In the figure 7 is shown case of preservation of the ex-
traction sockets and augmentation of alveolar ridge 
in the maxilla in region of tooth’s 14, 15 and 17. After 
extraction of the teeth, mucoperiosteal flap was done. 
Extraction sockets were fulfilled with sticky bone, 
which was covered with Bio-Oss collagen membrane 
and above all that PRF membrane was lay on. The flap 
was repositioned to its presurgical level and sutured 
with atraumatic silk string. Clinical healing was normal 
with neither inflammation nor untoward clinical symp-
toms. Postoperative clinical parameters showed that 
application of PRF achieved formation of new bone 
tissue and enough keratinized gingiva. It was there-
fore natural to capture whole volume of monocytes 
in the PRF, to make it more active in stimulating bone 
grafts, but also to turn to a more rapid transformation 
of monocytes into macrophages to increase the effect 
bone stimulation.
Figure 5. a) Bone surface with osteonecrosis, 
b) PRF tubes, c) PRF membranes, d) Removed bone 
with osteonecrosis, e) Applied PRF membrane, 
f) Status postoperative after one mount with 
formation of new soft tissue
Figure 6. a) Retro alveolar X-Ray of tooth 22, b) Sticky 
bone, c) Bone defect after enucleation of the radicular 
cyst and resection of the tooth apex, d) Done cavity 
filled with sticky bone, e) Sticky bone covered with PRF 
membrane, f) Post-operative status after two weeks
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Figure 7. Preservation of the extraction wound and 
augmentation of alveolar ridge: a) Status intraorally, 
radix gangrenosa 14, 15, 17, b) Applied sticky bone 
covered with Bio-Oss Collagen membrane and PRF 
membrane, c) Set suture, d) Post-operative 
status after 3 weeks
In figure 8 was presented a case where bony defect 
was consequence of wearing fix orthodontic bracelets. 
X-ray revealed lack of bone around the roots of first 
and second maxillary incisors. Incision was made cor-
responding to the number of adjacent one defect, ex-
tending to the line angles of both adjacent teeth that 
had no defect. Sticky bone made of spongious bone 
substitute and PRF exudate was applied in the bony 
defect and above that PRF membrane was lie on. Then, 
the mucogingival flap was repositioned as coronally 
as possible without tension with 6-0 nylon sutures. 
Patient was advised to abstain from brushing and 
flossing around the surgical area until suture removal 
(14 days after surgery). Control X-ray after 2 mounts 
showed formation of new bone tissue. 
3.2 Discussion
The use of platelet concentrates for healing, improve-
ment and regeneration of the soft and hard tissues in 
oral cavity is one of the latest achievements in dentist-
ry [18]. 
In our study we used PRF plugs in the sockets of ex-
tracted maxillary roots and oral cavity after removal of 
periapical lesion of tooth 22. With the use of PRF as a 
socket preservation material in our cases we confirmed 
that PRF enhances healing of soft and hard tissue and 
reduced postoperative complications. Our results are 
in correspondence with Sharma at all., and Moraschini 
and Barboza, [19, 20]. 
A-PRF+ and I-PRF are widely used either as a prophy-
lactic measure in terms of socket preservation [21] af-
ter tooth extraction to prevent jaw atrophy and sup-
port the wound healing or in combination with bone 
substitute materials [22] to accelerate and enhance the 
regeneration process in the bone augmentation bed 
and to provide enhanced bone formation. Moreover, 
soft-tissue regeneration in periodontology is a further 
representative field for the application of PRF-based 
matrices. In this context, PRF-based matrices are dis-
seminated in the treatment of chronic periodontitis 
[23] and the regeneration of gingival recession [24]. 
Furthermore, necrosis, such as bisphosphonate-as-
sociated osteonecrosis of the jaw, suffers from limit-
ed vascularization and impaired wound healing [28]. 
However, with the introduction of PRF, further mini-
mal invasive possibilities became available for clinical 
application. Consequently, the use of PRF as a mem-
brane or I-PRF injections showed promising clinical 
outcomes [29]. 
Thus, the application of A-PRF+ and I-PRF as a “biocat-
alyst” within the impaired region could accelerate the 
wound healing by providing the needed cells imme-
diately after injury so that less cell recruitment is re-
quired. The combination with biomaterials is a promis-
ing approach in guided bone and tissue regeneration 
to enhance the capacity of the applied biomaterials 
and to enhance their bioactivity [22]. 
Figure 8. a) Bony defect due to fix orthodontic bracelets, 
b) X-Ray before and after surgical intervention, 
c) Bone grafted material and suture used in 
intervention, d) Absence of the bone around the roots of 
first and second maxillary incisors, e) Made sticky bone, 
f) Applied sticky bone in the defect
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When we used PRF membranes in our cases for per-
forming ridge augmentation, we used them to protect 
and stabilize the graft materials. The membranes act 
as fibrin bandages, accelerating the healing of the soft 
tissues, facilitating the rapid closure of the incision de-
spite a substantial volume of added bone. 
The use of PRF during surgery increases their numbers 
attentional stage so healing there by playing a central 
role in the phagocytosis of debris, microbes and ne-
crotic tissues, as well as directing the future regenera-
tion of these tissues through release of cytokines and 
growth factors. 
Recently, studies have demonstrated that the PRF 
membrane has a very significant slow sustained re-
lease of many key growth factors (GF) for at least 1 
week [6] and up to 28 days, [23] which means that PRF 
could release GF with its own biological scaffold for 
wound healing process. 
PRF membrane helps in wound healing, protecting 
the surgical site [24], and promoting soft tissue repair; 
when mixed with bone graft, it may act as a “biological 
connector”, which attracts stem cell, favors the migra-
tion of osteoprogenitor cells to the center of the graft, 
and provides a neo-angiogenesis [25]. 
Cut PRF membranes in fragments and mixed with the 
graft material, who were applied in the surgical side in 
the second and third case were function as a biological 
connector between the different elements of the graft, 
and as a matrix which favors neo-angiogenesis, the 
capture of stem cell, and the migration of osteo-pro-
genitor cells to the center of the graft. These findings 
are in correlation with the results of Vence at all., and 
Hamdan at all., [26, 27]. 
Using the reported protocol, we observed high degree 
of gingival maturation after healing with a thickening 
of keratinized gingival tissue that improved the esthet-
ic integration and final result of their prosthetic reha-
bilitation. 
4. Conclusions
- Our clinical cases showed that PRF can be routinely 
used in oral surgery, with good biological effect and 
satisfactory clinical results under correct manipula-
tion. PRF after extraction improves the bone width and 
height and bone quality. 
- We concluded that PRF alone or in combination with 
other biomaterials seems to have several advantages 
and indications in oral surgery, due it is a minimally 
invasive technique with low risks and satisfactory re-
sults.
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